Aurora Cannabis (TSE:ACB – Get Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, February 9th. Analysts expect the company to announce earnings of C($0.09) per share for the quarter.
→ Cash Holders STILL Aren’t Taking Steps to Prepare (From Investor Place Media)
Aurora Cannabis (TSE:ACB – Get Rating) last announced its earnings results on Thursday, November 10th. The company reported C($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of C($0.13) by C$0.03. The company had revenue of C$49.26 million for the quarter, compared to analyst estimates of C$52.18 million.
Aurora Cannabis Trading Up 5.0 %
ACB opened at C$1.46 on Thursday. The company has a debt-to-equity ratio of 54.76, a current ratio of 4.07 and a quick ratio of 2.48. The company has a market cap of C$473.53 million and a price-to-earnings ratio of -0.24. The firm has a 50 day simple moving average of C$1.40 and a 200 day simple moving average of C$1.69. Aurora Cannabis has a fifty-two week low of C$1.11 and a fifty-two week high of C$6.22.
Analyst Ratings Changes
Separately, Stifel Nicolaus dropped their price target on shares of Aurora Cannabis from C$1.75 to C$1.45 in a research note on Friday, January 27th. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of C$2.49.
About Aurora Cannabis
(Get Rating)
Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, Caribbeans, South America, and Israel; and distribution and sale of hemp-derived cannabidiol (CBD) products in the United States (U.S.) market.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Aurora Cannabis, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aurora Cannabis wasn’t on the list.
While Aurora Cannabis currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Credit: Source link
